NWBio to present DCVax-L survival data at UK neuro-oncology meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
July 2, 2026 2:18 PM EDTBETHESDA, Md., July 2, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be making a scientific presentation entitled "DCVax-LAssociated Survival Extension Assessed Through Propensity Score Matching Analyses" at the 2026 Annual... More
